Popular Pre-Market Trades in US Stocks
Polaryx Therapeutics is down 4.11% in pre-market trading. Based on recent key news:
<ol>
<li>
On February 10, Polaryx Therapeutics released a new company announcement regarding its latest R&amp;D progress. This announcement attracted market attention, leading to a pre-market drop of 4.11%. Data source: GlobeNewswire.
</li>
<li>
Recently, market confidence in the biotechnology sector has declined, and investors have become more cautious about high-risk R&amp;D projects, further exacerbating the volatility of Polaryx Therapeutics' stock price.
</li>
<li>
Due to the uncertainty in the macroeconomic environment, investors are more stringent in assessing the investment risks of small biotechnology companies, affecting Polaryx Therapeutics' market performance. The biotechnology sector has shown weakness recently, leading to cautious investor sentiment.
</li>
</ol>
Top Gainers in Pre-Market US Stocks
Mint is up 83.46% in pre-market trading. Based on recent key news:
<ol>
<li>
On February 10, Mint Inc. announced a non-binding memorandum of cooperation with Rice Robotics, planning to invest approximately $10 million to establish a joint venture aimed at accelerating the development and deployment of intelligent robotic solutions. This news significantly boosted the stock price. Source: ACN Newswire.
</li>
<li>
On February 13, Benzinga's stock ranking indicated that Mint Inc. has shown a negative price trend across all time frames; nevertheless, the market remains optimistic about its collaboration with Rice Robotics. Source: Benzinga.
</li>
<li>
No other significant news recently. The robotics technology sector is developing rapidly, with noticeable capital inflows.
</li>
</ol>
Kebang Technology is up 48.52% in pre-market trading, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, this stock shows significant volatility, and specific reasons need further observation.
Iveda Solutions is up 29.14% in pre-market trading. Based on recent key news:
<ol>
<li>
On February 9, Iveda Solutions announced a public offering of 5,714,286 shares of common stock and Series X warrants, priced at $0.35 per share. This move aims to raise funds to support the company's future development, leading to stock price fluctuations.
</li>
<li>
On February 10, the pricing announcement of Iveda Solutions' public offering attracted market attention, causing the stock price to rise in pre-market trading. Investors are concerned about the company's future plans for fund utilization.
</li>
<li>
On February 10, Iveda Solutions' subsidiary in Taiwan released a forward-looking statement regarding the public offering, highlighting potential risks and uncertainties, which the market reacted positively to. The US stock market has seen increased volatility recently, and investors should exercise caution
</li>
</ol>

PLYX

Polaryx Therapeutics pre-market down 4.11%; Mint Incorporation pre-market up 83.46%; Kebo Technology pre-market up 48.52%; Iveda Solutions pre-market up 29.14%

Pre-market hot trades in US stocks: Polaryx Therapeutics pre-market down 4.11%, research and development progress failed to boost market confidence